Cyclerion Therapeutics, Inc. – NASDAQ:CYCN
Cyclerion Therapeutics stock price today
$2.38
-0.91
-27.88%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
Cyclerion Therapeutics stock price monthly change
-0.60%
month
Cyclerion Therapeutics stock price quarterly change
-0.60%
quarter
Cyclerion Therapeutics stock price yearly change
-21.61%
year
Cyclerion Therapeutics key metrics
Market Cap | 8.69M |
Enterprise value | N/A |
P/E | -0.33 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | 4.82 |
Price/Book | 0.88 |
PEG ratio | 0.03 |
EPS | -6.49 |
Revenue | N/A |
EBITDA | -7.06M |
Income | 149K |
Revenue Q/Q | N/A |
Revenue Y/Y | -100% |
Profit margin | -3665.14% |
Oper. margin | -3683.09% |
Gross margin | 0% |
EBIT margin | -3683.09% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCyclerion Therapeutics stock price history
Cyclerion Therapeutics stock forecast
Cyclerion Therapeutics financial statements
| Jun 2023 | 0 | -4.18M | |
|---|---|---|---|
| Sep 2023 | 0 | 7.56M | |
| Dec 2023 | 0 | -1.69M | |
| Mar 2024 | 0 | -1.54M |
| 2025 | 2.03M | -78.08M | -3833.54% |
|---|---|---|---|
| 2026 | 90.33M | -47.22M | -52.28% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 10097000 | 4.94M | 48.99% |
|---|---|---|---|
| Sep 2023 | 15214000 | 2.34M | 15.39% |
| Dec 2023 | 13374000 | 2.08M | 15.6% |
| Mar 2024 | 11364000 | 1.44M | 12.68% |
| Jun 2023 | -6.55M | 0 | 5.02M |
|---|---|---|---|
| Sep 2023 | -6.93M | 10.40M | 0 |
| Dec 2023 | -1.54M | -10.40M | 0 |
| Mar 2024 | -1.87M | 0 | 0 |
Cyclerion Therapeutics alternative data
| Aug 2023 | 16 |
|---|---|
| Sep 2023 | 16 |
| Oct 2023 | 16 |
| Nov 2023 | 16 |
| Dec 2023 | 16 |
| Jan 2024 | 16 |
| Feb 2024 | 16 |
| Mar 2024 | 1 |
| Apr 2024 | 1 |
| May 2024 | 1 |
| Jun 2024 | 1 |
| Jul 2024 | 1 |
Cyclerion Therapeutics other data
23.94%
-23.95%
of CYCN is owned by hedge funds
17
-20
10.40M
-10.41M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Nov 2024 | 0 | 357880 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | SLATE PATH CAPITAL LP 10 percent owner | Common Stock, no par value | 357,880 | $1.55 | $555,072 | ||
Sale | MCGUIRE TERRANCE director | Common Stock | 8 | $3.4 | $27 | ||
Purchase | SLATE PATH CAPITAL LP | Common Stock, no par value | 961,538 | N/A | N/A | ||
Purchase | MCGUIRE TERRANCE director | Common Stock | 96,153 | $3.12 | $299,997 | ||
Purchase | HECHT PETER M director, officer.. | Common Stock | 823,170 | $3.28 | $2,699,998 | ||
Purchase | HECHT PETER M director, officer.. | Common Stock | 302,000 | N/A | N/A | ||
Purchase | HECHT PETER M director, officer.. | Common Stock | 398,001 | $2.53 | $1,006,943 | ||
Purchase | HECHT PETER M director, officer.. | Common Stock | 300,000 | $2.29 | $687,000 | ||
Sale | WRIGHT CHRISTOPHER I | Common Stock | 2,637 | $3.99 | $10,522 | ||
Sale | GJINO ANJEZA | Common Stock | 1,824 | $4 | $7,296 |
| Patent |
|---|
Application Filling date: 30 Mar 2022 Issue date: 21 Jul 2022 |
Grant Filling date: 14 Sep 2018 Issue date: 19 Jul 2022 |
Grant Filling date: 31 Jan 2017 Issue date: 14 Jun 2022 |
Grant Filling date: 6 Jul 2017 Issue date: 3 May 2022 |
Grant Filling date: 10 Jan 2019 Issue date: 15 Mar 2022 |
Application Filling date: 8 Oct 2021 Issue date: 27 Jan 2022 |
Application Filling date: 27 Sep 2021 Issue date: 20 Jan 2022 |
Application Filling date: 27 Sep 2021 Issue date: 13 Jan 2022 |
Grant Utility: sGC stimulators Filling date: 13 Mar 2020 Issue date: 28 Dec 2021 |
Grant Utility: SGC stimulators Filling date: 7 Nov 2017 Issue date: 23 Nov 2021 |
-
What's the price of Cyclerion Therapeutics stock today?
One share of Cyclerion Therapeutics stock can currently be purchased for approximately $2.38.
-
When is Cyclerion Therapeutics's next earnings date?
Unfortunately, Cyclerion Therapeutics's (CYCN) next earnings date is currently unknown.
-
Does Cyclerion Therapeutics pay dividends?
No, Cyclerion Therapeutics does not pay dividends.
-
How much money does Cyclerion Therapeutics make?
Cyclerion Therapeutics has a market capitalization of 8.69M.
-
What is Cyclerion Therapeutics's stock symbol?
Cyclerion Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "CYCN".
-
What is Cyclerion Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Cyclerion Therapeutics?
Shares of Cyclerion Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Cyclerion Therapeutics's key executives?
Cyclerion Therapeutics's management team includes the following people:
- Dr. Andreas Busch Ph.D. Chief Scientific Officer(age: 62, pay: $662,420)
- Dr. Peter M. Hecht Ph.D. Chief Executive Officer, Interim Chief Financial Officer, Principal Accounting Officer & Director(age: 61, pay: $110,780)
-
How many employees does Cyclerion Therapeutics have?
As Jul 2024, Cyclerion Therapeutics employs 1 workers.
-
When Cyclerion Therapeutics went public?
Cyclerion Therapeutics, Inc. is publicly traded company for more then 6 years since IPO on 18 Mar 2019.
-
What is Cyclerion Therapeutics's official website?
The official website for Cyclerion Therapeutics is cyclerion.com.
-
Where are Cyclerion Therapeutics's headquarters?
Cyclerion Therapeutics is headquartered at 245 First Street, Cambridge, MA.
-
How can i contact Cyclerion Therapeutics?
Cyclerion Therapeutics's mailing address is 245 First Street, Cambridge, MA and company can be reached via phone at 857 327 8778.
Cyclerion Therapeutics company profile:
Cyclerion Therapeutics, Inc.
cyclerion.comExchange:
NASDAQ
Full time employees:
1
Industry:
Biotechnology
Sector:
Healthcare
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
245 First Street
Cambridge, MA 02142
Cambridge, MA 02142
CIK: 0001755237
ISIN: US23255M2044
CUSIP: 23255M105
